Kognitic, a premier entity in advanced AI-driven clinical and commercial intelligence, today launches a comprehensive one-stop solution for dynamically tracking and staying informed about ADCs, ADC payloads, and their MoAs. ADC, a rapidly growing therapeutic field in oncology, holds immense promise. Despite its potential, challenges such as toxicity and resistance persist. To address these issues, improving ADC design becomes crucial. For a comprehensive understanding of ADC targets, payloads, and their MoAs, Kognitic offers a powerful solution. Users can quickly access vital information, aiding in overcoming challenges and advancing ADC research.
The ADCs fuse a monoclonal antibody with a cytotoxic payload, offering a potential solution for various cancers, including breast, lung, and lymphomas. The augmented ADC filtering now provide pivotal information about the payload type, target, and mechanism of action, facilitating a precise identification of clinical trials.
"This advancement serves as a powerful tool for researchers and drug developers managing oncology clinical trials, assisting them to identify potential candidate ADCs for their pipeline," said Aqil Ahsan, CEO of Kognitic, expressing confidence that this new feature will accelerate the development and commercialization trajectories of ADC trials in the cancer treatment landscape.
Headquartered in Somerville, New Jersey, Kognitic stands alone as a leading provider of advanced AI-driven clinical and commercial intelligence. Offering access to a comprehensive database of visualized clinical trial reporting, along with powerful tools for effective management and commercialization of drug pipelines. Kognitic has received awards for being a top resource in biopharma informatics by Life Science Review and Health Care Tech Outlook, as well for its stunning visualizations and is regarded for the freshness of their data.
View source version on newsdirect.com: https://newsdirect.com/news/navigating-the-adc-frontier-kognitics-swift-adaptation-empowers-drug-developers-in-payload-tracking-839841673
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times journalist was involved in the writing and production of this article.